Scarica l'app Stockscreener
13.02
0.38%
-0.05
Pre-mercato:
12.95
-0.07
-0.54%
Precedente Chiudi:
$13.07
Aprire:
$13.145
Volume 24 ore:
1.41M
Relative Volume:
0.64
Capitalizzazione di mercato:
$887.85M
Reddito:
$2.73B
Utile/perdita netta:
$-1.13B
Rapporto P/E:
-0.7814
EPS:
-16.6622
Flusso di cassa netto:
$-83.00M
1 W Prestazione:
+9.78%
1M Prestazione:
+13.32%
6M Prestazione:
-52.39%
1 anno Prestazione:
-57.66%
Intervallo 1D:
$12.86
$13.28
Intervallo di 1 settimana:
$11.69
$13.57
Portata 52W:
$9.92
$35.58
Quidelortho Corp Stock (QDEL) Company Profile
Nome
Quidelortho Corp
Settore
Industria
Telefono
(858) 552-1100
Indirizzo
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corp
|
13.02 | 891.26M | 2.73B | -1.13B | -83.00M | -16.66 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quidelortho Corp Stock (QDEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-07 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-10 | Iniziato | Jefferies | Hold |
| 2024-09-19 | Ripresa | UBS | Neutral |
| 2024-09-05 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2024-03-04 | Downgrade | UBS | Neutral → Sell |
| 2024-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-14 | Aggiornamento | UBS | Sell → Neutral |
| 2022-09-19 | Iniziato | Citigroup | Neutral |
| 2022-07-20 | Iniziato | UBS | Sell |
| 2022-06-17 | Ripresa | JP Morgan | Neutral |
| 2022-02-22 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Ripresa | Raymond James | Strong Buy |
| 2018-03-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Reiterato | Barclays | Overweight |
| 2018-01-04 | Aggiornamento | CL King | Neutral → Buy |
| 2017-09-19 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Reiterato | Canaccord Genuity | Hold |
| 2017-02-17 | Iniziato | CL King | Neutral |
| 2016-12-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Reiterato | Barclays | Overweight |
| 2016-02-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Reiterato | Canaccord Genuity | Buy |
| 2015-12-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Iniziato | Barclays | Overweight |
| 2013-07-31 | Reiterato | Canaccord Genuity | Buy |
| 2011-03-03 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Quidelortho Corp Borsa (QDEL) Ultime notizie
QuidelOrtho (QDEL) reports Q1 loss, tops revenue estimates - MSN
QuidelOrtho Corp stock (US7476011036): director share purchase and CFO transition in focus - AD HOC NEWS
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $3 - GuruFocus
Director at QuidelOrtho (QDEL) receives 1,407 shares from RSU release - Stock Titan
QuidelOrtho Corp (QDEL) Stock Down 4.2% -- Now Undervalued? GF S - GuruFocus
How Quidelortho Corp Com (QDEL) Affects Rotational Strategy Timing - Stock Traders Daily
When Blood Compatibility Becomes a Pregnancy Risk – Company Announcement - Financial Times
QuidelOrtho stock (US7476011036): Shares rise after latest market move - AD HOC NEWS
When Blood Compatibility Becomes a Pregnancy Risk - Sahm
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences - Yahoo Finance
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25 - MSN
QuidelOrtho stock (US7476011036): Shares fall after recent after-hours pressure - AD HOC NEWS
QuidelOrtho Corp stock (US7476011036): analysts divided as short interest climbs and sentiment weake - AD HOC NEWS
5 Insightful Analyst Questions From QuidelOrtho’s Q1 Earnings Call - Yahoo Finance
QuidelOrtho Corp (QDEL) Shares Surge 3.0% -- What GF Score of 48 Tells Investors - GuruFocus
QuidelOrtho stock (US7476011036): Q1 loss narrows as shares stay under pressure - AD HOC NEWS
QuidelOrtho stock sinks to 52-week lowhere's why - MSN
QuidelOrtho: A Growing, Stable Business With A Significant Mispricing (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) Q1 2026 Earnings Transcript - AOL.com
QuidelOrtho (NASDAQ:QDEL) misses Q1 CY2026 revenue estimates - MSN
Deckers, Franklin, Eaton, Coupang, QuidelOrtho Trending Among Analysts - TipRanks
QuidelOrtho Corporation 2026 Q1ResultsEarnings Call Presentation (NASDAQ:QDEL) 2026-05-08 - Seeking Alpha
QuidelOrtho Corp stock (US7476011036): Q1 2026 loss widens as respiratory sales weaken - AD HOC NEWS
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
QuidelOrtho Is Maintained at Neutral by Citigroup - Moomoo
QuidelOrtho price target lowered to $12 from $17 at UBS - TipRanks
QuidelOrtho downgraded to Hold from Buy at Jefferies - TipRanks
UBS Adjusts Price Target on QuidelOrtho to $12 From $17, Maintains Neutral Rating - marketscreener.com
Jefferies Maintains QuidelOrtho(QDEL.US) With Hold Rating, Maintains Target Price $12.5 - Moomoo
Jefferies Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $12.50 From $35 - marketscreener.com
QuidelOrtho reports GAAP net loss of USD 92M in Q1 2026 - Medical Buyer
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR) - The Globe and Mail
QDEL SEC FilingsQuidel 10-K, 10-Q, 8-K Forms - Stock Titan
QuidelOrtho (QDEL) Loss Deepens In Q1 As Long Trailing Losses Challenge Bullish Narratives - simplywall.st
QuidelOrtho Balances Near-Term Strain With Recovery Plan - TipRanks
QUIDELORTHO Corporation Q1 2026 SEC 10-Q Filing: Financial Results, Risk Factors, and Management Discussion - Minichart
Invesco Ltd. reports 4.6% stake in QuidelOrtho (NASDAQ: QDEL) - Stock Titan
Newtyn Management (NASDAQ: QDEL) reports 4.56M shares, 6.7% holding - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $11.66 - Moomoo
QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2026 Earnings Call Transcript - Insider Monkey
QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty - MSN
QuidelOrtho : Quarterly Report for Quarter Ending March 29, 2026 (Form 10-Q) - marketscreener.com
QDEL Q1 Deep Dive: Softer Respiratory Demand and China Headwinds Drive Guidance Reset - The Globe and Mail
QuidelOrtho Q1 2026 slides: revenue falls 13%, respiratory weakness pressures margins - Investing.com Nigeria
QuidelOrtho Q1 Earnings Call Highlights - Yahoo Finance
QuidelOrtho Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: QuidelOrtho Q1 2026 results miss expectations - Investing.com UK
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Quidelortho Corp Azioni (QDEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):